Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study
© Piranda et al; licensee BioMed Central Ltd. 2010
Received: 6 January 2010
Accepted: 8 November 2010
Published: 8 November 2010
Cyclooxygenase-2 (COX-2) is up-regulated in several types of cancer, and it is hypothesized that COX-2 expression may be genetically influenced. Here, we evaluate the association between single-nucleotide polymorphisms (SNPs) in the COX-2 gene (PTGS2) and the occurrence of breast cancer among Brazilian women.
The study was conducted prospectively in two steps: First, we screened the promoter region and three fragments of the 3'-untranslated region of PTGS2 from 67 healthy Brazilians to identify SNPs and to select those with a minor allele frequency (MAF) of at least 0.10. The MAF of these selected SNPs was further characterized in 402 healthy volunteers to evaluate potential differences related to heterogeneous racial admixture and to estimate the existence of linkage disequilibrium among the SNPs. The second step was a case-control study with 318 patients and 273 controls designed to evaluate PTGS2 genotype- or haplotype-associated risk of breast cancer.
The screening analysis indicated nine SNPs with the following MAFs: rs689465 (0.22), rs689466 (0.15), rs20415 (0.007), rs20417 (0.32), rs20419 (0.015), rs5270 (0.02), rs20424 (0.007), rs5275 (0.22) and rs4648298 (0.01). The SNPs rs689465, rs689466, rs20417 and rs5275 were further studied: Their genotypic distributions followed Hardy-Weinberg equilibrium and the MAFs were not affected by gender or skin color. Strong linkage disequilibrium was detected for rs689465, rs20417 and rs5275 in the three possible pairwise combinations. In the case-control study, there was a significant increase of rs5275TC heterozygotes in cases compared to controls (OR = 1.44, 95% CI = 1.01-2.06; P = 0.043), and the haplotype formed by rs689465G, rs689466A, rs20417G and rs5275C was only detected in cases. The apparent association with breast cancer was not confirmed for rs5275CC homozygotes or for the most frequent rs5275C-containing haplotypes.
Our results indicate no strong association between the four most frequent PTGS2 SNPs and the risk of breast cancer.
Cyclooxygenases (COXs) are key enzymes in mediating the conversion of free arachidonic acid into prostaglandin H2, the precursor of molecules such as prostaglandins, prostacyclin and thromboxanes . Two isoforms of cyclooxygenase (COX-1 and COX-2) are known. The constitutive cyclooxygenase (COX-1) is present in many tissues and synthesizes prostaglandins involved in maintaining normal tissue homeostasis . The inflammatory enzyme COX-2 is not detected in most normal tissues but can be induced by cytokines, growth factors or tumor promoters. COX-2 catalyzes the synthesis of prostaglandins, such as prostaglandin E2 (PGE2), which can affect cell proliferation, apoptosis and angiogenesis , contributing to tumor progression. COX-2 is present in several types of solid tumors and, in breast cancer, is associated with parameters of aggressiveness, including tumor size, positive nodal status and lower survival [4, 5]. In addition, inhibition of COX-2 by nonsteroidal anti-inflammatory drugs has been associated with a protective effect against a variety of cancers  and may be effective in the prevention and treatment of breast cancer [7, 8].
The mechanisms involved in the regulation of COX-2 expression remain unclear and may be influenced by genetic variations. The human COX-2 gene, PTGS2, is located on chromosome 1 (locus q25.2-q25.3), is 8.3 kb in size, contains 10 exons and produces an mRNA of 4.6 kb. The analysis of the promoter region (PR) reveals the existence of several potential regulatory elements, including a TATA box and transcription binding sites for NF-kB, NF-IL6, AP-1, AP-2, GAS, TBP and cAMP response element. Several genetic variants have been described in regions next to these regulatory sites that may affect enzyme expression [9, 10] and contribute to a greater risk of developing cancer.
In addition to variations in the PR, sites in the 3'-untranslated region (3'-UTR) of the gene may also be associated with increased risk of developing cancer. The 3'-UTR of the PTGS2 gene contains 30 AUUUA elements. Such repetitions generate consensus binding sequences for proteins and inflammatory mediators that regulate the stability and degradation of mRNA [11–13]. These repeats are also present in other genes encoding inflammatory mediators (cytokines and proto-oncogenes) whose mRNAs are very unstable . Genetic variations in the 3'-UTR of the PTGS2 gene may contribute to increased stability of mRNA and the synthesis of COX-2.
The frequency of SNPs in the PTGS2 gene may vary between different ethnic groups [15, 16]. No data are available on the frequency of such variant forms in the Brazilian population, either in healthy subjects or in cancer patients. The high rate of racial admixture, with a major contribution from Europeans and Africans in the formation of the Brazilian population, suggests that the variant forms of the PTGS2 gene may have a high prevalence in Brazil and that their occurrence may lead to haplotypes with different potentials for changes in COX-2 expression.
In the present study, we identified single-nucleotide polymorphisms (SNPs) in the PR and 3'-UTR of the PTGS2 gene and evaluated their association with breast cancer occurrence among Brazilians.
Experimental Design and Study Population
This study was conducted prospectively in two steps: first, we screened 1.5 kb of the PR and three fragments comprising 1.2 kb of the 3'-UTR of the PTGS2 gene in 67 healthy Brazilians to identify PTGS2 SNPs and to select those with a minor allele frequency (MAF) of at least 0.10. The frequency of these selected SNPs was further characterized in 355 other healthy volunteers (comprising a total of 402) to evaluate potential differences in allelic distribution due to heterogeneous racial admixture. We adopted the classification scheme used in the 2000 Brazilian Census , which relies on self-perception of skin color. Accordingly, the individuals were distributed into the following three color groups: white, black and intermediate. The term "color" (cor in Portuguese) is preferred to "race" in Brazil because it captures the continuous aspects of phenotypes and also because a racial descent rule is not operational in this country . The color stratification was not intended as an accurate ethnic classification. Instead, our objective was to evaluate potential differences in the frequency distribution of PTGS2 SNPs to ascertain if an independent population control would be necessary in the case-control study.
The second step was a case-control study, designed to evaluate the genotype-associated risk of breast cancer for the most prevalent PTGS2 SNPs, i.e., those with at least 0.10 MAF. This case-control study involved 318 women with breast cancer and 273 healthy controls. The patients had a confirmed diagnosis of breast cancer based on histopathological evaluation and were under current treatment at the Brazilian National Cancer Institute. The patients were assigned a recruitment interview when scheduled for routine blood exams. The controls were non-related healthy women with no signs or symptoms of breast cancer who were recruited among patients' escorts, hospital staff and blood donors of the Brazilian National Cancer Institute. The recruitment of both patients and controls occurred between January and October 2008.
All volunteers were informed about the procedures of the study and gave written consent to participate. Patients and controls were interviewed by trained personnel using a questionnaire to determine demographic and lifestyle characteristics. Information on clinical history was obtained from medical records for patients (N = 250) and collected in an additional questionnaire for controls (N = 183). The study was approved by the Ethics Committee of the Brazilian National Cancer Institute (Protocol #116/07).
SNP Screening and Genotyping
Peripheral blood samples (3 mL) were collected from all subjects (volunteers, cases and controls). DNA was extracted using the DNAzol system (Invitrogen Life Technologies, Carlsbad, USA), following the procedures recommended by the manufacturer and were used to search for SNPs of the PTGS2 gene (GenBank accession #AY382629). The blood samples were kept at 4°C until DNA extraction, which was performed within 24 h of blood collection.
Nucleotide PRIMER sequences and PCR conditions for genotyping by dHPLC or PCR-RFLP
Number of cycles
In the case of dHPLC analysis, all samples with chromatographic profiles suggestive of variation in the gene sequence were analyzed using ABI PRISM-377 equipment (TaqMan, PE Biosystems, Foster City, CA, USA). A portion of controls (10% of the samples) was also analyzed by automatic sequencing, and the results matched completely.
The four SNPs selected for the case-control study were genotyped with the same sets of primers used in the screening step. The SNPs rs689465, rs689466 and rs20417 could not be identified by dHPLC and were genotyped by PCR-RFLP (Table 1).
Allelic and genotypic frequencies were derived by gene counting and the adherence to the Hardy-Weinberg principle was evaluated by the chi-square test for goodness-of-fit. The evaluation of pairwise linkage disequilibrium was performed using the Fisher exact test, available on-line in GENEPOP (http://genepop.curtin.edu.au/; ), whereas the haplotype patterns were inferred using Haploview (http://www.broadinstitute.org/haploview; ), based on the algorithm of expectation and maximization. Comparisons of demographic and clinical features and of genotypic and haplotypic distributions between patients and controls were performed using the chi-square test for proportions. Univariate logistic regression analyses were performed to identify independent factors influencing the risk of developing breast cancer, which was estimated by the odds ratio (OR) with 95% confidence interval (95% CI). The threshold for significance was set at P < 0.05 (Pearson P-value). The clinically relevant factors with independent effects on breast cancer risk (OR and 95% CI >1) were used to create a multivariate final model using the Enter method. All statistical analyses were conducted using SPSS 13.0 for Windows (SPSS Inc., Chicago, Illinois).
The screening analysis of the PR and 3'-UTR of the PTGS2 gene in 67 healthy Brazilians revealed the existence of nine SNPs, which occurred with the following MAFs: -1290AG (rs689465, 0.22); -1195AG (rs689466, 0.15); -1131GA (rs20415, 0.007); -765GC (rs20417, 0.32), -604TC (rs20419, 0.015), -163CG (rs5270, 0.02), -62CG (rs20424, 0.007), 8473TC (rs5275; 0.22) and 9850AG (rs4648298; 0.01). The SNP 10335GA (rs689469), which was reported to have a MAF of 0.02 among the Spanish , was not found.
Minor allelic frequency (MAF) of PTGS2 SNPs in Brazilians
Pairwise linkage disequilibrium between PTGS2 SNPs in Brazilians
rs689465 & rs689466
rs689465 & rs20417
rs689466 & rs20417
rs689465 & rs5275
rs689466 & rs5275
rs20417 & rs5275
Impact of clinical and demographic characteristics on the risk of breast cancer in Brazilian women
First Birth (Age)
≥ 31 or nulliparous
Use of contraceptives †
Use of HRT θ
Use of NSAIDs
Underweight: ≤ 18.4
Normal: 18.5 - 24.9
Overweight: ≥ 25.0
Genotypic distribution of PTGS 2 SNPs in cases and controls
Genotypic Distribution N (Freq)
Haplotype distribution in patients and controls and association with breast cancer risk
G A CC
G AG C
A G GT
AA C T
G A C T
A GC T
In the past five years, several studies have aimed to evaluate the impact of PTGS2 SNPs on the risk of developing different types of cancer [10, 15, 16, 21–46]. However, most of these studies evaluated only one or a few SNPs at a time, sometimes with no clear selection criteria. Zhang et al.  were the first to perform a screening strategy to identify the most frequent PTGS2 SNPs. This approach was also preferred in our case, due to the heterogeneity of the Brazilian population and to the consequent hazards of using frequency data obtained elsewhere.
In our screening strategy, we evaluated 1.5 kb of the PR and 1.2 kb of the 3'-UTR, which encompass the most important regulatory sites of PTGS2 expression [9, 10, 13]. The focus on the regulatory regions of the gene is justified by the fact that PTGS2 mRNA is very unstable , and an increase in its stability promotes COX-2 expression in colon cancer cells . In addition, in vitro studies indicate possible functional effects of the SNPs rs689466 and rs20417 on PTGS2 promoter activity (evaluated by a luciferase gene reporter system) [9, 10] and on COX-2 activity (evaluated by PGE2 production in human monocytes) . Although screening the entire PTGS2 gene would be theoretically preferable because variants in the coding and non-coding regions could tag other functional SNPs, previous reports involving these variants suggest no significant effect on COX-2 activity  or on cancer risk [16, 21, 25, 28–30, 32, 33, 35–43, 45, 46]. The only exception is a recent publication by Zhao et al. , which suggests an increased risk of esophageal squamous cancer associated to SNP rs20432 that is located in intron 5. This positive association, however, is not confirmed in other types of cancer [16, 21, 25, 29, 33, 36, 45].
In our screening analysis, we found nine SNPs, five of which showed very low MAFs (approximately 0.01): rs20415, rs20419, rs5270, rs20424 and rs4648298. These MAFs are in accordance with previous reports involving different populations [15, 16, 50]. The SNPs rs689465, rs689466, rs20417 and rs5275 were selected for the case-control study and appear to be the most frequent SNPs in other Western populations [16, 21, 23, 25, 51–58].
The present work is the first study on the frequency of PTGS2 SNPs among Brazilians, who are one of the world's most heterogeneous populations as a result of extensive interethnic crosses over the last 500 years between autochthonous Amerindians, European colonizers and Africans [59–61]. Studies based on population-specific alleles, blood groups and electrophoresis of protein markers have outlined the hazards of equating color or race with geographic ancestry in Brazilians [18, 59–63]. Thus, the stratification of our population into three groups based on self-reported skin color (white, intermediate and black) was not intended for ethnic classification but to evaluate potential differences in the frequency of PTGS2 SNPs due to heterogeneous racial admixture. Because no significant difference in the genotype distribution was detected for the four SNPs among the color groups, either in the general population or among patients (data not shown), no population control or stratification based on continental-specific alleles was necessary in the case-control study.
In the present study, there was no association between rs689465, rs689466 or rs20417 and the occurrence of breast cancer. The results for rs689466 and rs20417 are in accordance with previously published data [23, 25, 39]. This is the first report on rs689465 and the risk of breast cancer.
Our results show an increase in the frequency of rs5275 TC heterozygotes among patients compared to controls, with an apparent increased risk of breast cancer development after adjustment for age differences. The borderline significance of this association, however, limits its confidence. The number of subjects in our case-control study was initially calculated considering the allele frequencies in the general population and a possible 2-fold increase in the rs5275 MAF among patients, with a significance level of 5% and an error level of 20%. Although the actual sample size was larger than first estimated to ensure statistical power, it was still small for the evaluation of inheritance models or for the study of the less frequent haplotypes.
A review of the literature concerning the impact of rs5275 on the risk of breast cancer shows conflicting results. Langsenlehner et al.  found that carriers of the rs5275 C allele in the Austrian population were more frequent among breast cancer patients (34.8%) than among age-matched controls (29.9%; P = 0.018), with an increased risk of breast cancer in rs5275CC homozygotes (OR = 2.1; 95% CI = 1.3-3.3; P = 0.002). These results, however, were not corroborated by other authors. Vogel et al.  found no association between rs5275 genotype and breast cancer susceptibility, which was confirmed in three independent large studies [25, 28, 39]. Cox et al. , combining data from three separate studies in the American population (N = 5144), indicated that women homozygous for the rs5275 C allele have a 20% lower risk of breast cancer than those homozygous for the T allele (OR = 0.80, 95% CI = 0.66-0.97) . This reduced risk was confirmed by Zhu et al.  in a meta-analysis, which, however, did not include the large number of individuals in the work by Abraham et al.  and by Dossus et al. . Taken together, these studies appear to suggest no strong influence of rs5275 SNP on breast cancer risk.
The present work indicates that variants in the PR and in the 3' UTR of PTGS2 do not appear to greatly influence breast cancer risk, as the apparent risk association found for rs5275 SNP was limited to heterozygotes with a low OR value and borderline significance. However, the apparently negative results do not exclude potential low risks (i.e., OR < 1.5), whose detection with high level of statistical significance (P < 0.001) would require large individual studies or meta-analysis (N > 6000). Our data also highlight the existence of various PTGS2 haplotypes that have not been thoroughly studied and should be considered for further evaluation of risk association with cancer development and/or progression.
Our results indicate no strong association between the four most frequent PTGS2 SNPs and the risk of breast cancer.
We thank all volunteers and patients who participated in this study. We also would like to thank Dr. Guilherme Suarez-Kurtz for the use of laboratory facilities.
This work was supported by grants from Fundação Carlos Chagas Filho de Amparo à Pesquisa no Rio de Janeiro - FAPERJ (E-26/170.721/2007, E-26/110.374/2007) and from INCT para Controle do Câncer (Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq 573806/2008-0, FAPERJ E26/170.026/2008). D. N. Piranda received a scholarship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
- Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB: Arachidonic acid metabolism. Annu Rev Biochem. 1986, 55: 69-102. 10.1146/annurev.bi.55.070186.000441.View ArticlePubMedGoogle Scholar
- Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996, 271: 33157-160. 10.1074/jbc.271.52.33157.View ArticlePubMedGoogle Scholar
- Zha S, Yegnasubramanian ZS, Nelson WG, Isaacs WB, De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Letters. 2004, 205: 1-20. 10.1016/j.canlet.2004.06.014.View ArticleGoogle Scholar
- Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al: Prognostic significance of elevated cyclooxygenase expression in breast cancer. Cancer Res. 2002, 62: 632-635.PubMedGoogle Scholar
- Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, et al: Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. British J of Cancer. 2003, 88 (4): 574-578. 10.1038/sj.bjc.6600741.View ArticleGoogle Scholar
- Pereg D, Lishner M: Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med. 2005, 258: 115-23. 10.1111/j.1365-2796.2005.01519.x.View ArticlePubMedGoogle Scholar
- Arun B, Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004, 31: 22-9. 10.1053/j.seminoncol.2004.03.042.View ArticlePubMedGoogle Scholar
- Bundred NJ, Barnes NL: Potential use of COX-2-aromatase inhibitor combinations in breast cancer. British J of Cancer. 2005, 93 (Suppl 1): S10-5. 10.1038/sj.bjc.6602690.View ArticleGoogle Scholar
- Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al: Common promoter variant in cyclooxygenase-2 repress gene expression. Arterioscler Thromb Vasc Biol. 2002, 22: 1631-1636. 10.1161/01.ATV.0000030340.80207.C5.View ArticlePubMedGoogle Scholar
- Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al: Identification of functional genetic variants in Cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005, 129: 565-576.PubMedGoogle Scholar
- Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A: Identification of a common nucleotide sequence in the 3'-unstranlated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA. 1986, 83: 1670-4. 10.1073/pnas.83.6.1670.View ArticlePubMedPubMed CentralGoogle Scholar
- Di Marco S, Hel Z, Lachance C, Furneaux H, Radzioch D: Polymorphism in the 3'-unstranlanted region of TNFα mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFα mRNA. Nucleic Acid Res. 2001, 29: 863-71. 10.1093/nar/29.4.863.View ArticlePubMedPubMed CentralGoogle Scholar
- Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM: Post-transcriptional Control of Cyclooxygenase-2 Gene Expression. The Journal of Biological Chemistry. 2000, 275 (16): 11750-11757. 10.1074/jbc.275.16.11750.View ArticlePubMedGoogle Scholar
- Nabors LB, Gillespie GY, Harkins L, King PH: HuR, a stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3'-unstranlated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 2001, 61: 2154-61.PubMedGoogle Scholar
- Panguluri RCK, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, et al: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004, 25: 961-6. 10.1093/carcin/bgh100.View ArticlePubMedGoogle Scholar
- Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, et al: Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. British J of Cancer. 2004, 91: 339-43.Google Scholar
- CENSO 2000. Accessed Nov 28, 2007, [http://www.ibge.gov.br/home/estatistica/populacao/censo2000/]
- Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 2003, 100: 177-82. 10.1073/pnas.0126614100.View ArticlePubMedGoogle Scholar
- Raymond M, Rousset F: GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity. 1995, 86: 248-249.Google Scholar
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, [PubMed ID: 15297300]Google Scholar
- Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004, 25: 229-35. 10.1093/carcin/bgh008.View ArticlePubMedGoogle Scholar
- Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O: A genetic polymorphism in prostaglandin synthase 2 (8473, T/C) and the risk of lung cancer. Cancer Letters. 2005, 226: 49-54. 10.1016/j.canlet.2005.03.037.View ArticlePubMedGoogle Scholar
- Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Research. 2006, 6 (8): R71-10.1186/bcr1629.View ArticleGoogle Scholar
- Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Weber B, et al: The Cyclooxygenase-2 (PTGS2) 8473T > C Polymorphismis Associated with Breast Cancer Risk. Clin Cancer Res. 2006, 12 (4): 1392-94. 10.1158/1078-0432.CCR-05-2055.View ArticlePubMedGoogle Scholar
- Cox DG, Buring J, Hankinson SE, Hunter DJ: A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Research. 2007, 9 (1): R3-10.1186/bcr1635.View ArticlePubMedPubMed CentralGoogle Scholar
- Fernandez P, de Beer PM, van der Merwe L, Heyns CF: COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis. 2008, 29: 2347-2350. 10.1093/carcin/bgn245.View ArticlePubMedGoogle Scholar
- Upadhyaya R, Jain M, Kumarb S, Ghoshalc UC, Mittala B: Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutation Research. 2009, 663: 52-59.View ArticleGoogle Scholar
- Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, et al: Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Research. 2009, 15 (6): 2181-91. 10.1158/1078-0432.CCR-08-0716.View ArticleGoogle Scholar
- Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang W-Y, et al: Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis. 2008, 3 (29): 568-572.Google Scholar
- Li F, Ren GS, Li HY, Wang XY, Chen L, Li J: A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol (R Coll Radiol). 2009, 4: 302-5.View ArticleGoogle Scholar
- Lin YC, Huang HI, Wang LH, Tsai CC, Lung O, Dai CY, et al: Polymorphisms of COX-2 -765G > C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008, 44 (8): 798-804. 10.1016/j.oraloncology.2007.10.006.View ArticlePubMedGoogle Scholar
- Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007, 97 (4): 557-61. 10.1038/sj.bjc.6603874.View ArticlePubMedPubMed CentralGoogle Scholar
- Shahedi K, Lindström S, Zheng SL, Wiklund F, Adolfsson J, Sun J, et al: Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006, 119 (3): 668-72. 10.1002/ijc.21864.View ArticlePubMedGoogle Scholar
- Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjønneland A: Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007, 28 (9): 2062-10.1093/carcin/bgm181.View ArticleGoogle Scholar
- Lee TS, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS: Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci. 2007, 1095: 134-42. 10.1196/annals.1397.017.View ArticlePubMedGoogle Scholar
- Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006, 15 (6): 1126-31. 10.1158/1055-9965.EPI-06-0042.View ArticlePubMedGoogle Scholar
- Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ: Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer. 2006, 119 (2): 297-303. 10.1002/ijc.21858.View ArticlePubMedGoogle Scholar
- Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, Li L: No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol. 2009, 15 (18): 2240-4. 10.3748/wjg.15.2240.View ArticlePubMedPubMed CentralGoogle Scholar
- Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, et al: PTGS2 and IL6 Genetic Variation and Risk of Breast and Prostate Cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2009, 31 (3): 455-61. 10.1093/carcin/bgp307.View ArticlePubMedPubMed CentralGoogle Scholar
- Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P, Ambinder RF, et al: Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 976-86. 10.1158/1055-9965.EPI-08-1130.View ArticlePubMedPubMed CentralGoogle Scholar
- Hou L, Grillo P, Zhu ZZ, Lissowska J, Yeager M, Zatonski W, et al: COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res. 2007, 27 (6C): 4243-7.PubMedGoogle Scholar
- Moorman PG, Sesay J, Nwosu V, Kane JG, de Cotret AR, Worley K, Millikan R: Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. Cancer Epidemiol Biomarkers Prev. 2005, 14 (12): 3013-4. 10.1158/1055-9965.EPI-05-0291.View ArticlePubMedGoogle Scholar
- Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, et al: Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology. 2006, 130 (7): 1975-84. 10.1053/j.gastro.2006.03.021.View ArticlePubMedGoogle Scholar
- Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al: Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007, 28 (6): 1197-201. 10.1093/carcin/bgl242.View ArticlePubMedGoogle Scholar
- Ali IU, Luke BT, Dean M, Greenwald P: Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer. 2005, 93 (8): 953-9. 10.1038/sj.bjc.6602806.View ArticlePubMedPubMed CentralGoogle Scholar
- Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, et al: Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis. 2006, 27 (6): 1251-6. 10.1093/carcin/bgi314.View ArticlePubMedGoogle Scholar
- Szczeklik W, Sanak M, Szczeklik A: Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial Asthma. J Allergy Clin Immunol. 2004, 114 (2): 248-253. 10.1016/j.jaci.2004.05.030.View ArticlePubMedGoogle Scholar
- Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA: Functional Characterization of Cyclooxygenase-2 Polymorphisms. The Journal of Pharmacology and Experimental Therapeutics. 2001, 299 (2): 468-76.PubMedGoogle Scholar
- Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, et al: Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009, 136 (5): 1659-68. 10.1053/j.gastro.2009.01.071.View ArticlePubMedGoogle Scholar
- SeattleSNP. Seattle, WA: NHLBI Program for Genomic Applications, (accessed every month between Jan - Oct/2008), [http://pga.gs.washington.edu]
- Gallicchio L, Mcsorley MA, Newschaffer CJ, Huang HY, Hoffman SC, Helzlsouer KJ: Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006, 106 (7): 10.1002/cncr.21763.Google Scholar
- Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al: PTGS2 (COX-2) -765G > C Promoter Variant Reduces Risk of Colorectal Adenoma among Nonusers of Nonsteroidal Anti-inflammatory Drugs. Cancer Epidemiol biomarkers Prev. 2005, 14 (3): 10.1158/1055-9965.EPI-04-0510.Google Scholar
- Vogel U, Christensen J, Walin H, Friis S, Nexø BA, Tjønneland A: Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutation Research. 2007, 617: 138-146.View ArticlePubMedGoogle Scholar
- Lira MG, Mazzola S, Tessari SG, Malerba G, Ortombina M, Nald L, et al: Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol. 2007, 157 (1): 49-57. 10.1111/j.1365-2133.2007.07921.x.View ArticlePubMedGoogle Scholar
- Hakansson A, Bergman O, Chrapkowska C, Westberg L, Belin AC, Sydow O, et al: Cyclooxygenase-2 polymorphisms in parkinson's disease. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics). 2007, 144B: 367-369. 10.1002/ajmg.b.30449.View ArticleGoogle Scholar
- Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee RYL: Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. Journal of Thrombosis and Haemostasis. 2006, 4: 1718-1722. 10.1111/j.1538-7836.2006.02054.x.View ArticlePubMedGoogle Scholar
- Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT, et al: Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the atherosclerosis risk in communities study shun. Atherosclerosis. 2008, 196: 926-930. 10.1016/j.atherosclerosis.2007.02.010.View ArticlePubMedGoogle Scholar
- Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, et al: The cyclooxygenase 2 -765C promoter allele is a protective factor for Alzheimer's disease. Neuroscience Letters. 2005Google Scholar
- Salzano FM, Freire-Maia N: Problems in human biology -- a study of Brazilian populations. 1970, Detroit: Wayne State University Press, 54-8.Google Scholar
- Dornelles CL, Callegari-Jacques SM, Robinson WM, Weimer TA, Franco MHLP, Hickmann AC, et al: Genetics, surnames, grandparents' nationalities and ethnic admixture in Southern Brazil: do the patterns of variation coincide?. Genet Mol Biol. 1999, 22: 151-61. 10.1590/S1415-47571999000200003.View ArticleGoogle Scholar
- Alves-Silva J, Santos MS, Guimarães PE, Ferreira AC, Bandelt HJ, Pena SD, et al: The ancestry of Brazilian mtDNA lineages. Am J Hum Genet. 2000, 67: 444-61. 10.1086/303004.View ArticlePubMedPubMed CentralGoogle Scholar
- Sans M: Admixture studies in Latin America: from the 20th to the 21st century. Hum Biol. 2000, 72: 155-77.PubMedGoogle Scholar
- Krieger H, Morton NE, Mi MP, Azevedo E, Freire-Maia A, Yasuda N: Racial admixture in north-eastern Brazil. Ann Hum Genet. 1965, 29: 113-25. 10.1111/j.1469-1809.1965.tb00507.x.View ArticlePubMedGoogle Scholar
- Zhu W, Wei BB, Shan X, Liu P: -765G > C and 8473T > C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep. 2009, Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/613/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.